Skip to content

Tetranectin as a Novel Obesity-associated Adipokine for Regulating Lipid Accumulation

Tetranectin as a Novel Obesity-associated Adipokine for Regulating Lipid Accumulation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03229044
Enrollment
289
Registered
2017-07-25
Start date
2005-12-06
Completion date
2008-12-05
Last updated
2017-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Obesity

Keywords

adipokine, tetranectin, lipid metabolism, body mass index

Brief summary

Adipose tissue is strongly correlated to obesity and diabetes which are two major problems in the worldwide. Adipose tissue is involved in modulating glucose and energy metabolism locally and systemically by secreting factors, called adipocytokines. Tetranectin (TN), a novel adipocytokine, is secreted by adipose tissues. TN may regulate the glucose/energy homeostasis to affect lipid accumulation.The role of TN in adipocytes with or without TN on regulation of adipose tissue growth and lipid metabolism is valuable to be studied. Materials and methods: Secreted proteins from human adipocyte culture medium were deciphered using 2-D polyacrylamide gel electrophoresis and determined by LC/MS with MALDI-TOF analysis of proteins. Adipose tissues were obtained from the breast of 15 women undergoing mastectomy. Serum samples from 200 normal healthy people and 54 breast cancer patients were assigned to either a lean or obese group according to the body mass index. The TN protein concentration was measured in the culture medium of stromal-vascular fraction (SVF)-derived adipocytes from healthy humans, breast cancer patients, pigs and also from 3T3-L1 cells. Associations between plasma TN and other biomarkers were assessed with Pearson's correlations and multivariable linear regression.

Detailed description

Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. All participants gave permission and the study was approved by the Ethics Committee of National Taiwan University Hospital as no. 9461701203. From 2012 to 2013 in National Taiwan University Hospital, a cross-sectional sampling of 21 to 78 -year old people included women and men who were living in Taiwan. Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. Fasting serum samples were obtained from 193 randomly selected persons having health check-ups. To investigate the relationship among TN and breast cancer, fasting serum samples also obtained from 54 randomly selected breast cancer patients who were 25 to 59 years old with elected surgery for breast cancer stage 0 and 1.

Interventions

GENETICTetranectin

Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Must be above age 20 years old. 2. Subjects must sign the written informed consent form. 3. Must have residual fat after surgery. 4. Clinical diagnosis of liposuction and tumor resection.

Exclusion criteria

1. Terminal cancer. 2. Subjects have no fat tissue after surgery. 3. Pregnant subjects.

Design outcomes

Primary

MeasureTime frameDescription
Tetranectin expression measurethrough study completion, an average of 2 yearsDetect Tetranectin expression in adipose tissue by qPCR or Western blotting

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026